| Lastest Insider Transactions Of Intra-Cellular Therapies, Inc. ( ITCI ) |
| Symbol | Company Name | Insider Name | Title | Date | Transation | Share | Price | Amount | File Date |
| ITCI | Intra-Cellular Therapies, Inc. | RIGGS RORY B | Directior | 2024-03-20 | Option Exercise | 20,000 | 18.56 | 371,200 | 2024-03-22 16:12:23 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2024-03-07 | Sell | 61,277 | 66.07 | 4,048,400 | 2024-03-11 20:33:20 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2024-03-07 | Option Exercise | 20,565 | 0.00 | 0 | 2024-03-11 20:33:20 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance, CFO | 2024-03-07 | Sell | 23,253 | 66.32 | 1,542,147 | 2024-03-11 20:33:11 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance, CFO | 2024-03-07 | Option Exercise | 10,121 | 25.44 | 257,497 | 2024-03-11 20:33:11 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2024-03-07 | Sell | 20,477 | 66.09 | 1,353,235 | 2024-03-11 20:32:14 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2024-03-07 | Option Exercise | 7,345 | 0.00 | 0 | 2024-03-11 20:32:14 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2024-03-07 | Sell | 20,477 | 66.23 | 1,356,110 | 2024-03-11 20:31:47 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2024-03-07 | Option Exercise | 7,345 | 0.00 | 0 | 2024-03-11 20:31:47 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | EVP, Chief Medical Officer | 2024-03-07 | Sell | 10,162 | 66.21 | 672,791 | 2024-03-11 20:31:31 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | EVP, Chief Medical Officer | 2024-03-07 | Option Exercise | 7,345 | 0.00 | 0 | 2024-03-11 20:31:31 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2024-03-06 | Option Exercise | 13,132 | 0.00 | 0 | 2024-03-08 17:59:18 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2024-03-06 | Option Exercise | 40,712 | 0.00 | 0 | 2024-03-08 17:59:02 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2024-03-06 | Option Exercise | 13,132 | 0.00 | 0 | 2024-03-08 17:58:45 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance, CFO | 2024-03-06 | Option Exercise | 13,132 | 0.00 | 0 | 2024-03-08 17:58:27 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | EVP, Chief Medical Officer | 2024-03-06 | Option Exercise | 13,132 | 0.00 | 0 | 2024-03-08 17:58:07 |
| ITCI | Intra-Cellular Therapies, Inc. | VAN NOSTRAND ROBERT L | Directior | 2024-02-27 | Sell | 20,000 | 72.93 | 1,458,650 | 2024-02-28 19:41:57 |
| ITCI | Intra-Cellular Therapies, Inc. | VAN NOSTRAND ROBERT L | Directior | 2024-02-27 | Option Exercise | 20,000 | 18.56 | 371,200 | 2024-02-28 19:41:57 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2024-02-23 | Sell | 7,907 | 69.53 | 549,784 | 2024-02-27 20:00:20 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2024-02-23 | Option Exercise | 7,907 | 0.00 | 0 | 2024-02-27 20:00:20 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance, CFO | 2024-02-23 | Sell | 13,337 | 69.43 | 925,961 | 2024-02-27 20:00:06 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance, CFO | 2024-02-23 | Option Exercise | 13,337 | 16.27 | 216,987 | 2024-02-27 20:00:06 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2024-02-23 | Sell | 22,590 | 69.79 | 1,576,464 | 2024-02-27 19:59:36 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2024-02-23 | Option Exercise | 22,590 | 0.00 | 0 | 2024-02-27 19:59:36 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | EVP, Chief Medical Officer | 2024-02-23 | Sell | 4,112 | 70.17 | 288,534 | 2024-02-27 19:58:39 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | EVP, Chief Medical Officer | 2024-02-23 | Option Exercise | 7,907 | 0.00 | 0 | 2024-02-27 19:58:39 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2024-02-23 | Sell | 7,907 | 70.13 | 554,491 | 2024-02-27 19:58:07 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2024-02-23 | Option Exercise | 7,907 | 0.00 | 0 | 2024-02-27 19:58:07 |
| ITCI | Intra-Cellular Therapies, Inc. | MARCUS JOEL S | Directior | 2024-02-26 | Sell | 26,328 | 68.68 | 1,808,253 | 2024-02-27 19:57:35 |
| ITCI | Intra-Cellular Therapies, Inc. | MARCUS JOEL S | Directior | 2024-02-26 | Option Exercise | 36,757 | 48.93 | 1,798,678 | 2024-02-27 19:57:35 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2024-02-01 | Sell | 11,860 | 66.42 | 787,719 | 2024-02-05 18:13:07 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2024-02-01 | Sell | 33,885 | 67.07 | 2,272,694 | 2024-02-05 18:10:42 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2024-02-01 | Sell | 11,860 | 67.15 | 796,368 | 2024-02-05 18:07:48 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance, CFO | 2024-02-01 | Sell | 11,183 | 66.62 | 745,037 | 2024-02-05 18:05:03 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | EVP, Chief Medical Officer | 2024-02-01 | Sell | 6,167 | 67.19 | 414,355 | 2024-02-05 18:02:20 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2024-01-16 | Sell | 191,362 | 66.27 | 12,680,892 | 2024-01-18 19:47:15 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2024-01-16 | Option Exercise | 191,362 | 16.86 | 3,226,363 | 2024-01-18 19:47:15 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2024-01-11 | Sell | 50,000 | 66.83 | 3,341,699 | 2024-01-12 18:02:47 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2024-01-11 | Option Exercise | 50,000 | 13.60 | 680,051 | 2024-01-12 18:02:47 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | EVP, Chief Medical Officer | 2024-01-02 | Sell | 62,282 | 70.60 | 4,397,113 | 2024-01-04 19:54:57 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | EVP, Chief Medical Officer | 2024-01-02 | Option Exercise | 62,282 | 19.87 | 1,237,543 | 2024-01-04 19:54:57 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | EVP, Chief Medical Officer | 2023-12-13 | Sell | 21,262 | 65.00 | 1,382,030 | 2023-12-15 17:01:51 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2023-11-06 | Sell | 42,393 | 55.63 | 2,358,152 | 2023-11-08 17:31:41 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2023-11-06 | Option Exercise | 26,754 | 23.94 | 640,491 | 2023-11-08 17:31:41 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2023-09-18 | Sell | 100,000 | 53.94 | 5,394,065 | 2023-09-19 20:40:33 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2023-08-07 | Sell | 55,300 | 58.79 | 3,251,087 | 2023-08-09 18:05:36 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2023-08-07 | Option Exercise | 55,300 | 18.59 | 1,028,027 | 2023-08-09 18:05:36 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | EVP, Chief Medical Officer | 2023-07-17 | Sell | 1,842 | 65.00 | 119,730 | 2023-07-20 17:47:53 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance CFO | 2023-06-14 | Sell | 81,854 | 63.97 | 5,236,330 | 2023-06-16 17:05:14 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance CFO | 2023-06-14 | Option Exercise | 81,854 | 42.30 | 3,462,317 | 2023-06-16 17:05:14 |
| ITCI | Intra-Cellular Therapies, Inc. | VAN NOSTRAND ROBERT L | Directior | 2023-04-17 | Sell | 10,000 | 63.00 | 630,000 | 2023-04-19 18:00:22 |
| ITCI | Intra-Cellular Therapies, Inc. | VAN NOSTRAND ROBERT L | Directior | 2023-04-17 | Option Exercise | 10,000 | 13.05 | 130,500 | 2023-04-19 18:00:22 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2023-03-28 | Sell | 15,604 | 54.31 | 847,380 | 2023-03-30 17:08:31 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | EVP, Chief Medical Officer | 2023-03-10 | Sell | 7,344 | 45.04 | 330,794 | 2023-03-13 19:36:05 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | EVP, Chief Medical Officer | 2023-03-10 | Option Exercise | 7,344 | 0.00 | 0 | 2023-03-13 19:36:05 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2023-03-09 | Sell | 12,308 | 43.84 | 539,599 | 2023-03-13 19:35:04 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2023-03-09 | Option Exercise | 7,344 | 0.00 | 0 | 2023-03-13 19:35:04 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2023-03-09 | Sell | 24,052 | 43.66 | 1,050,092 | 2023-03-13 19:34:06 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2023-03-09 | Option Exercise | 7,344 | 0.00 | 0 | 2023-03-13 19:34:06 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance CFO | 2023-03-09 | Sell | 21,245 | 43.55 | 925,225 | 2023-03-13 19:32:47 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance CFO | 2023-03-09 | Option Exercise | 5,582 | 0.00 | 0 | 2023-03-13 19:32:47 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2023-03-09 | Sell | 62,335 | 43.76 | 2,727,841 | 2023-03-13 19:31:19 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2023-03-09 | Option Exercise | 40,565 | 1.61 | 65,200 | 2023-03-13 19:31:19 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2023-03-01 | Sell | 7,241 | 50.01 | 362,122 | 2023-03-03 19:03:35 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2023-02-23 | Sell | 4,046 | 47.12 | 190,648 | 2023-02-27 20:03:12 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2023-02-23 | Option Exercise | 7,906 | 0.00 | 0 | 2023-02-27 20:03:12 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | SVP, Chief Medical Officer | 2023-02-23 | Sell | 7,906 | 47.14 | 372,689 | 2023-02-27 20:02:34 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | SVP, Chief Medical Officer | 2023-02-23 | Option Exercise | 7,906 | 0.00 | 0 | 2023-02-27 20:02:34 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2023-02-23 | Sell | 7,906 | 47.03 | 371,819 | 2023-02-27 20:01:36 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2023-02-23 | Option Exercise | 7,906 | 0.00 | 0 | 2023-02-27 20:01:36 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance CFO | 2023-02-23 | Sell | 7,455 | 47.03 | 350,609 | 2023-02-27 20:00:54 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance CFO | 2023-02-23 | Option Exercise | 7,455 | 0.00 | 0 | 2023-02-27 20:00:54 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2023-02-23 | Sell | 22,590 | 47.03 | 1,062,408 | 2023-02-27 19:59:46 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2023-02-23 | Option Exercise | 52,590 | 1.86 | 97,800 | 2023-02-27 19:59:46 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2023-02-18 | Sell | 3,898 | 47.01 | 183,246 | 2023-02-22 20:05:55 |
| ITCI | Intra-Cellular Therapies, Inc. | Neumann Mark | EVP, Chief Commercial Officer | 2023-02-18 | Option Exercise | 11,139 | 0.00 | 0 | 2023-02-22 20:05:55 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | SVP, Chief Medical Officer | 2023-02-18 | Sell | 8,354 | 46.84 | 391,304 | 2023-02-22 20:04:37 |
| ITCI | Intra-Cellular Therapies, Inc. | Durgam Suresh K. | SVP, Chief Medical Officer | 2023-02-18 | Option Exercise | 8,354 | 0.00 | 0 | 2023-02-22 20:04:37 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2023-02-18 | Sell | 11,139 | 46.84 | 521,699 | 2023-02-22 20:03:14 |
| ITCI | Intra-Cellular Therapies, Inc. | Halstead Michael | EVP and General Counsel | 2023-02-18 | Option Exercise | 11,139 | 0.00 | 0 | 2023-02-22 20:03:14 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance CFO | 2023-02-18 | Sell | 64,411 | 49.34 | 3,178,354 | 2023-02-22 20:02:15 |
| ITCI | Intra-Cellular Therapies, Inc. | Hineline Lawrence J. | SVP of Finance CFO | 2023-02-18 | Option Exercise | 64,411 | 10.67 | 687,013 | 2023-02-22 20:02:15 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2023-02-18 | Sell | 27,848 | 46.83 | 1,304,000 | 2023-02-22 20:01:12 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2023-02-18 | Option Exercise | 27,848 | 0.00 | 0 | 2023-02-22 20:01:12 |
| ITCI | Intra-Cellular Therapies, Inc. | MARCUS JOEL S | Directior | 2022-12-19 | Sell | 5,000 | 50.82 | 254,100 | 2022-12-21 16:06:49 |
| ITCI | Intra-Cellular Therapies, Inc. | Mates Sharon | Chairman, President & CEO | 2022-12-13 | Sell | 33,083 | 55.00 | 1,819,565 | 2022-12-15 19:01:28 |
